While Aβ pathology is often considered a key initiator of AD development (potentially through facilitating the spread of tau pathology, Busche & Hyman, 2020), the phosphorylation, release and aggregation of tau proteins are tightly linked to the clinical and biological progression of AD (Savva et al, 2009; Nelson et al, 2012; Jack & Holtzman, 2013; Spires‐Jones & Hyman, 2014; Mattsson‐Carlgren et al, 2020a). The gene discussed is MAPT; the disease is Alzheimer disease.